# US 10,307,479 B2 · Therapy-enhancing glucan

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,307,479 B2
- Document ID: US10307479B2
- Status: Granted
- Kind: B2
- Application number: 15/338,805
- Filed: 2016-10-31
- Published: 2017-08-17
- Granted: 2019-06-04
- Earliest claimed: 2001-01-16
- Assignees: Sloan-Kettering Institute for Cancer Research
- Applicants: Sloan-Kettering Institute for Cancer Research
- Inventors: Nai-Kong V. Cheung
- Web page: https://patentgrep.com/patent/US10307479B2

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 31/716: Glucans
- A61K 31/739: Lipopolysaccharides
- A61K 39/39541: {against normal tissues, cells}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 39/44: Antibodies bound to carriers
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C08B 37/0024: {beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof}
- A61K 2039/55583: {Polysaccharides}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)

## Abstract

This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.

## Claims

### Claim 1

A method of enhancing the antitumor effect of an antibody in a subject suffering from cancer, comprising administering to said subject said antibody, and a β-(1,3)-glucan obtained from oat, wheat, or moss, in an amount effective to enhance the anti-tumor effect of said antibody, wherein said glucan alone has little or no effect on said cancer, and has a molecular weight from about 40,000 to about 359,000 Daltons.

### Claim 2 (depends on 1)

The method of claim 1, wherein said antibody is a complement-activating antibody.

### Claim 3 (depends on 1)

The method of claim 1, wherein said antibody is a monoclonal antibody.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cells of said cancer express CD20, HER2, EGFR, GD2 or GD3.

### Claim 5 (depends on 1)

The method of claim 1, wherein said cancer is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma and epidermoid carcinoma.